BOLT vs USB · rev $7.7M vs P/E 12, rev $28.66B
Bolt Biotherapeutics (BOLT) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
BOLT currently screens at market cap $11.3M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the BOLT and USB stock pages for the full models.
Not investment advice.